Skip to content

Diabetes mellitus

The reference is the ADA Standards of Care in Diabetes, updated every January in a supplement to Diabetes Care. The 2026 edition is summarised here.

ADA 2026

International Current

Standards of Care in Diabetes—2026

Official source

What's new in recent editions

  • Organ protection first: SGLT2i and GLP-1 RA choices are driven by ASCVD, heart failure, CKD and MASLD, irrespective of A1C.
  • GLP-1-based therapy before insulin for most people with type 2 diabetes.
  • Tirzepatide (dual GIP/GLP-1 RA) for obesity with HFpEF, and for weight.
  • SGLT2i can continue below eGFR 20 until dialysis; GLP-1 RA can be used on dialysis.
  • LDL goal <55 mg/dL (1.4 mmol/L) with established ASCVD.
  • Finerenone with an SGLT2i for diabetic kidney disease with albuminuria.

Clinical pearls

  • Euglycaemic DKA with SGLT2 inhibitors: ketoacidosis with near-normal glucose.
  • A1C is unreliable in pregnancy, haemoglobin variants, G6PD deficiency, HIV and anything that changes red-cell turnover: use glucose.
  • Over-basalisation: a big bedtime-to-morning or postprandial-to-preprandial drop, hypoglycaemia or high variability means too much basal insulin.